Matching slides 303,780
Current window 202,711-202,740
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

202,711-202,740 of 303,780

filter-aware
05
The slide features the LumiraDx device on the right and a series of test cartridge icons on the left.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
06
The slide presents a snapshot of company growth from 2019 to Q2 2022, including instrument shipments, manufacturing capacity, market reach, and revenue.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
07
The chart uses a waterfall-style visualization to show segments contributing to a total market size.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
08
Uses a process flow diagram to contrast current state (central lab) vs future state (POC).LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
09
The slide uses a list of pain points on the left and illustrative examples of existing POC devices on the right.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
10
Uses a photo of a lab bench to illustrate the 'proliferation of instruments' pain point.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
LumiraDx | Investor Presentation Deck | 55 slidesLumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The slide uses a color-coded border system to distinguish between test types (Qualitative/Quantitative Immunoassay, Enzyme, Molecular).LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
The chart uses a Gantt-style visualization to show progress across different diagnostic modalities.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
The slide showcases the physical device and a series of color-coded test cartridges for various conditions (COVID-19, HbA1c, D-Dimer, etc.).LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
LumiraDx | Investor Presentation Deck | 55 slidesLumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
16
The visual shows four distinct test strips (INR, D-Dimer, SARS CoV-2 Ab, SARS CoV-2 Ag) to demonstrate the 'common architecture' claim.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
17
The slide uses a numbered process flow (1-8) to explain the technical mechanism of the assay.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
18
LumiraDx | Investor Presentation Deck | 55 slidesLumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
19
The chart uses a bar-vertical format to show relative pricing, with LumiraDx POC positioned as significantly cheaper than other POC solutions.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
20
The diagram uses concentric circles to represent layers of IP protection (Manufacturing, Assays, Microfluidic Strip, Instrument).LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
21
The slide uses a horizontal arrow at the bottom to represent the strategic shift toward 'Decentralization'.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
22
The slide displays the physical device on the right and a row of 10 distinct test cartridges on the left, representing the product pipeline.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
23
LumiraDx | Investor Presentation Deck | 55 slidesLumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
24
The slide uses a scatter plot to demonstrate method comparison between LumiraDx and a laboratory reference (bioMérieux Vidas).LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
25
The slide uses two line charts to compare positivity rates across different test methods (LumiraDx, PCR, Other POC) over time, segmented by COVID-19 variants.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Evidence1 hit
26
The slide uses a bulleted list for key value propositions and a table to demonstrate clinical sensitivity (PPA) across different Ct value thresholds.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Evidence1 hit
27
The slide uses a blue dashed box to highlight key differentiators for the company's product.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Evidence1 hit
28
The scatter plot shows a high correlation (R^2 = 0.9868) between the two testing methods.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Evidence1 hit
29
The slide uses a process diagram to explain the workflow and a combination of line charts and a comparison table to demonstrate performance feasibility.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Evidence1 hit
30
The chart shows a significant drop-off in the TB care cascade, framing the opportunity for a POC test to improve linkage to care.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations Beat · Evidence1 hit
31
The slide illustrates a 3-step process: Prep Sample, Load & Run, and Report Results, with a timeline of 1 minute for prep and 2-12 minutes for results.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
32
Uses a visual 'before/after' style comparison with red X marks to indicate legacy/displaced systems.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
33
The table shows a progression from Year 1 to Year 2, and a second Year 2 column, likely representing a ramp-up or optimization scenario.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit
34
The slide uses a product-centric layout to demonstrate market readiness and addressable market size for a portfolio of diagnostic tests.LumiraDx | Investor Presentation Deck | 55 slides · LumiraDx
Pitch deck Investor relations 1 hit